These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 32678721

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine.
    Lipton RB, Lee L, Saikali NP, Bell J, Cohen JM.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1344-1352. PubMed ID: 32678720
    [Abstract] [Full Text] [Related]

  • 3. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ, Lee J, Knievel K, McVige J, Wang W, Wu Z, Gillard P, Shah D, Blumenfeld AM.
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Economic Burden of Illness in Adult Patients with Nocturia.
    Dmochowski R, Brucker BM, Cole E, Kawahara S, Pulicharam R, Burk C, Tung A, Hale D.
    J Manag Care Spec Pharm; 2019 May; 25(5):593-604. PubMed ID: 30675816
    [Abstract] [Full Text] [Related]

  • 9. Patients' perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom.
    Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S.
    J Headache Pain; 2018 Sep 10; 19(1):82. PubMed ID: 30203163
    [Abstract] [Full Text] [Related]

  • 10. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.
    J Manag Care Spec Pharm; 2018 Jun 10; 24(6):525-533. PubMed ID: 29799328
    [Abstract] [Full Text] [Related]

  • 11. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
    Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Florio AD, Dietch D, Geddes JR, Goodwin GM, Grunze H, Hayes JF, Jones I, Kasper S, Macritchie K, McAllister-Williams RH, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA.
    Br J Psychiatry; 2019 Jan 10; 214(1):27-35. PubMed ID: 30520709
    [Abstract] [Full Text] [Related]

  • 12. United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.
    Gibbs SN, Shah S, Deshpande CG, Bensink ME, Broder MS, Dumas PK, Buse DC, Vo P, Schwedt TJ.
    Headache; 2020 Jul 10; 60(7):1351-1364. PubMed ID: 32369201
    [Abstract] [Full Text] [Related]

  • 13. Ketamine: stimulating antidepressant treatment?
    Malhi GS, Byrow Y, Cassidy F, Cipriani A, Demyttenaere K, Frye MA, Gitlin M, Kennedy SH, Ketter TA, Lam RW, McShane R, Mitchell AJ, Ostacher MJ, Rizvi SJ, Thase ME, Tohen M.
    BJPsych Open; 2016 May 10; 2(3):e5-e9. PubMed ID: 27703782
    [Abstract] [Full Text] [Related]

  • 14. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
    Ford JH, Schroeder K, Nyhuis AW, Foster SA, Aurora SK.
    J Manag Care Spec Pharm; 2019 Jan 10; 25(1):46-59. PubMed ID: 30044691
    [Abstract] [Full Text] [Related]

  • 15. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
    Newsome SD, Aliotta PJ, Bainbridge J, Bennett SE, Cutter G, Fenton K, Lublin F, Northrop D, Rintell D, Walker BD, Weigel M, Zackowski K, Jones DE.
    Int J MS Care; 2016 Jan 10; 18(6):314-323. PubMed ID: 27999526
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey.
    Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T.
    J Headache Pain; 2020 Sep 10; 21(1):110. PubMed ID: 32912187
    [Abstract] [Full Text] [Related]

  • 18. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
    Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R.
    J Manag Care Spec Pharm; 2022 Aug 10; 28(8):818-829. PubMed ID: 35876297
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M, Cai Q, Cappell K, Kim G, Sapra SJ, Shah N, Widnell K, Winner P, Desai P.
    J Manag Care Spec Pharm; 2017 Nov 10; 23(11):1169-1176. PubMed ID: 29083975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.